2024年

感染症グループ

原著論文: 症例報告を含む

1. Hayakawa K, Saito S, Miyoshi-Akiyama T, Fukui Y, Takemoto N, Hashimoto T, Inagaki T, Hirose K, Kobayashi K, Koizumi R, Endo M, Komatsubara M, Nomoto H, Inada M, Ide S, Kamegai K, Ashida S, Nagata N, Kato H, Ohmagari N. Comparison of the effects of cefmetazole and meropenem on microbiome: A pilot study. J Infect Chemother, 30(12):1274-1279, 2024.
2. Nishigaki T, Tanaka K, Kawasaki R, Hashiguchi S, Kato H. Totally Implantable Central Venous Access Port-Associated Bloodstream Infection Caused by Corynebacterium provencense. Cureus, 16(10):e71250, 2024.
3. Sano K, Kurosawa T, Horikawa K, Kimura Y, Goto A, Ryo A, Hasegawa H, Kato H, Miyakawa K. Cellular and humoral immunity and IgG subclass distribution after omicron XBB.1.5 monovalent vaccination in Japan. Vaccine, 42(26):126452, 2024.
4. Tanaka K, Meguro A, Hara Y, Endo L, Izawa A, Muraoka S, Kaneko A, Somekawa K, Hirata M, Otsu Y, Matsumoto H, Nagasawa R, Kubo S, Murohashi K, Aoki A, Fujii H, Watanabe K, Horita N, Kato H, Kobayashi N, Takeuchi I, Nakajima A, Inoko H, Mizuki N, Kaneko T. HLA-DQA1*01:03 and DQB1*06:01 are risk factors for severe COVID-19 pneumonia. HLA, 104(1):e15609, 2024.